Exciting alternatives: An overview of long-acting HIV treatment, prevention
Acknowledging that even singletablet regimens may pose challenges to achieving viral suppression in many patients - including pill fatigue, tolerability, toxicity concerns and HIVrelated stigma - the focus has now shifted to long-acting (LA) ART. Oral lead-in therapy may be pursued to ensure tolerab...
Gespeichert in:
Veröffentlicht in: | Infectious Disease News 2022-10, Vol.35 (10), p.5-5 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Acknowledging that even singletablet regimens may pose challenges to achieving viral suppression in many patients - including pill fatigue, tolerability, toxicity concerns and HIVrelated stigma - the focus has now shifted to long-acting (LA) ART. Oral lead-in therapy may be pursued to ensure tolerability, and similar to cabotegravir/rilpivirine in combination, it is well tolerated, with the most common adverse reaction being injection site reactions. The International Partnership for Microbicides (IPM) withdrew its new drug application for FDA consideration because of the unlikelihood of approval in the U.S., a move that primarily affected women of racial and ethnic minority groups in a country where they are already disproportionately affected and may benefit the most. |
---|---|
ISSN: | 1056-9251 |